|Title:||Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies||Authors:||CHIA-YU CHU||Keywords:||Atopic dermatitis; Dupilumab; Eczema; Emerging treatment; Pruritus||Issue Date:||2020||Publisher:||Springer||Source:||Clinical Reviews in Allergy and Immunology||Abstract:||
Atopic dermatitis (AD) is generally considered a T helper type 2–dominated disease. Pediatric AD is usually less severe than adult AD, but it may present as moderate to severe lesions that are inadequately managed by current modalities including emollients/moisturizers, topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and even systemic immunosuppressants (such as cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil). In addition, systemic immunosuppressants are often not recommended for childhood AD by the current guidelines due to their toxicities. Therefore, there is still an unmet need for a safe and effective long-term therapy for pediatric AD patients whose disease is inadequately controlled or who are intolerant to current treatments. The emerging therapeutics for AD focuses on intervening in the inflammatory pathway by targeting specific cytokines/chemokines or their receptors. Monoclonal antibodies against immunoglobulin E (IgE), interleukin (IL)-4 receptor subunit α, IL-5, IL-13, IL-31 receptor subunit α, IL-33, and thymic stromal lymphopoietin (TSLP) have been evaluated clinically for AD. Encouraging results have been reported for many of the biologics, of which the most exciting is dupilumab. Other emerging systemic therapies include small molecules such as baricitinib, abrocitinib, upadacitinib, and tradipitant. Several novel topical agents are under clinical investigation for the treatment of AD, including topical phosphodiesterase 4 (PDE4) inhibitors, Janus kinase (JAK) inhibitors, aryl hydrocarbon receptor (AhR) modulating agents, and transient receptor potential vanilloid subfamily member 1 (TRPV1) antagonists. Accompanied by thorough characterization of different phenotype and endotype subsets, the application of precision medicine could provide new prospects for the optimal treatment of AD. ? 2020, Springer Science+Business Media, LLC, part of Springer Nature.
|ISSN:||1080-0549||DOI:||10.1007/s12016-020-08799-1||metadata.dc.subject.other:||dermatological agent; immunosuppressive agent; Janus kinase inhibitor; animal; atopic dermatitis; child; human; Animals; Child; Dermatitis, Atopic; Dermatologic Agents; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.